Composite minimax robust optimization of VMAT improves target coverage and reduces non-target dose in head and neck cancer patients.

BACKGROUND AND PURPOSE

To assess the potential of composite minimax robust optimization (CMRO) compared to planning target volume (PTV)-based optimization for head and neck cancer (HNC) patients treated with volumetric modulated arc therapy (VMAT).

MATERIALS AND METHODS

Ten HNC patients previously treated with a PTV-based VMAT plan were studied. In addition to the PTV-plan a VMAT plan was created with CMRO. For both plans an adapted planning strategy was also investigated, including a plan adaptation during the third week of treatment. The PTV-plans and CMRO-plans (adapted and non-adapted) were evaluated by means of the estimated actually given dose (EAGD). Therefore, the dose was calculated on daily acquired CBCTs, mapped onto the planning CT and accumulated. The plans were compared by dosimetric parameters and normal tissue complication probabilities (NTCPs) for tube feeding dependence, grade 2-4 dysphagia and xerostomia. The accuracy of CBCT-based dose accumulation was further quantified by comparisons of dose accumulation on weekly verification CTs.

RESULTS

On average, CMRO significantly increased (1.5 Gy) the D of the EAGD to the clinical target volume and significantly decreased the mean dose of the ipsilateral parotid (2.8 Gy), inferior pharynx constrictor muscle (0.7 Gy) and the oral cavity (0.8 Gy). This translated into significantly reduced NTCP of tube feeding dependence (0.9%) and xerostomia (2.8%). The differences in EAGD derived from evaluation CTs or CBCTs were minimal.

CONCLUSION

Minimax robust optimization led to improved target coverage and dose reduction in organs at risk in HNC patients treated with VMAT.